DNA damage and genomic instability are central both to the evolution and treatment of cancer. As a result, in recent years, much interest has focused on cellular DNA damage responses and whether these can be manipulated for therapy.[@R1] DNA damage activates a complex, interacting web of DNA repair and cell cycle checkpoint processes that offer a diverse range of potentially druggable targets.[@R1] These include multiple protein kinases that signal the presence of damage, such as ATM, ATR, Chk1 and Chk2, but also enzymes involved in DNA repair per se such as PARP-1 and MGMT.[@R2]

Chk1 in particular has attracted attention as a target for drug development, largely because it is a key effector of multiple cell cycle checkpoint responses triggered by both DNA damage and replication arrest.[@R2] Preclinical evaluation of Chk1 inhibitors has generally concentrated on determining whether checkpoint override can potentiate tumor cell killing by conventional genotoxic agents. Many published studies support this concept, and some, although not all, found greater potentiation in cells lacking p53 function, suggesting a mechanism of tumor selectivity. More recently, however, interest in the therapeutic potential of Chk1 inhibitors as single agents has been growing. Some tumor cells at least appear to be crucially dependent on Chk1 for proliferation and survival, perhaps because oncogene activation creates endogenous DNA damage or replication stress.[@R3]^,^[@R4]

In a recent paper in *Cell Cycle*,[@R5] Carrassa and colleagues noted that a panel of tumor cell lines varied greatly in their inherent sensitivity to a Chk1 inhibitor, PF00477736. Postulating that this might reflect variable expression of unknown factors exhibiting "synthetic lethal" interactions with Chk1, they undertook an siRNA screen for protein kinases whose depletion synergized with Chk1 inhibition.[@R5] Remarkably, the top hit in this screen was Wee1, a dual-specificity protein kinase that catalyzes inhibitory phosphorylation of Cdk1 (primarily on tyrosine 15; Y15). This modification increases as cells progress though the cell cycle, restraining Cdk1 catalytic activity until the onset of mitosis, when Y15 phosphorylation is abruptly reversed through the action of Cdc25 phosphatases ([Fig. 1](#F1){ref-type="fig"}).

![**Figure 1.** Regulation of Cdk1 inhibitory phosphorylation during normal cell cycle progression (A) In S- and G~2~-phases the catalytic activity of Cdk1:cyclin B1 complexes is restrained by inhibitory phosphorylation of tyrosine 15 (Y15), a modification catalyzed primarily by the Wee1 kinase. Cdk1 is also subject to inhibitory phosphorylation on threonine 14; however, this is omitted here for clarity. Entry to mitosis is triggered by rapid removal of Cdk1 Y15 when the activity of Cdc25 phosphatases outstrips that of Wee1 as a result of multiple positive feedback loops.[@R8] In response to DNA damage, Chk1 is activated and triggers G~2~ checkpoint arrest by inhibiting Cdc25 activity and thus maintaining Cdk1 in its Y15 phosphorylated, inactive state while damage persists. PF-00477736 is a Chk1 inhibitor which can override DNA damage-induced G~2~ arrest by preventing inhibition of Cdc25 phosphatases by Chk1. MK-1775 is a potent and selective inhibitor of Wee1 kinase. (B) During normal cell cycle progression, Y15 phosphorylated, inactive Cdk1:cyclin B complexes accumulate during S-phase and G~2~. Only at the end of G~2~ does Cdc25 phosphatase activity rise rapidly to abruptly dephosphorylate and activate Cdk1 and thus trigger the onset of mitosis.[@R8] Carrassa et al. demonstrate that concurrent inhibition of Chk1 and Wee1 using a combination of PF-00477736 and MK-1775 causes a wide range of tumor cell lines to arrest in S-phase and then to enter mitosis prematurely with partially replicated DNA leading to mitotic catastrophe and cell death. The S-phase arrest could be due to high levels of replication fork stalling and collapse, which have been shown to occur when Chk1 is inhibited or, alternatively, because premature entry to mitosis extinguishes DNA replication. The unscheduled dephosphorylation and activation of Cdk1 that leads to premature entry to mitosis most likely results from unrestrained Cdc25 phosphatase activity combined with inhibition of the normal tonic level of Wee1 Y15 kinase activity present in S-phase.](cc-11-2777-g1){#F1}

Carrassa et al. demonstrate that whereas siRNA depletion of Chk1 or Wee1 individually is relatively innocuous, simultaneous depletion of both led to high levels of spontaneous cell death in a wide range of tumor lines.[@R5] Importantly, synergistic cell killing was also obtained using PF00477736 in combination with a small-molecule inhibitor of Wee1, MK-1775, indicating that this synthetic lethal effect can be reproduced pharmacologically. Interestingly, toxicity did not correlate with the p53 status of the tumor cell lines, nor was synergy observed in non-transformed MRC-5 cells, suggesting that synthetic lethality depends on some generic but as-yet-unknown feature of the tumor cell phenotype.[@R5]

Prolonged maintenance of Cdk1 Y15 phosphorylation via Chk1-mediated inhibition of Cdc25 phosphatases forms an important component of the G~2~ arrest mechanism that prevents cells with damaged DNA entering mitosis ([Fig. 1](#F1){ref-type="fig"}), but what is the basis for synergistic cell killing by combined inhibition of Chk1 and Wee1 in the absence of exogenous genotoxic stress? Carrassa et al. observed that cells treated with a combination of Chk1 and Wee1 inhibitors arrested in S-phase of the cell cycle but, strangely, were no longer active in DNA synthesis.[@R5] Tellingly, levels of Cdk1 inhibitory phosphorylation were severely diminished, and consistent with this, morphological analysis revealed that many of these S-phase cells had entered a premature mitosis characterized by partially replicated, pulverized chromosomes and malformed mitotic spindles.[@R5] Some of these cells subsequently proceeded to die by apoptosis; however, it seems unlikely that such a catastrophic short-circuit from S-phase to mitosis would be survivable in any case ([Fig. 1](#F1){ref-type="fig"}).

This and other recent studies[@R6]^,^[@R7] reveal a more extensive role for Wee1 in cell cycle regulation than was previously known and highlight its potential as an anticancer drug target. But can this synthetic lethal principle of short-circuiting the cell cycle through combined inhibition of Chk1 and Wee1 really be extended to the clinic? Only time will tell, but it is promising that the combination of Chk1 and Wee1 inhibitors potently inhibited the growth of tumor xenografts in vivo with little toxicity as well as killing cells in vitro. As always, more research is needed!

Previously published online: [www.landesbioscience.com/journals/cc/article/21392](http://www.landesbioscience.com/journals/cc/article/21392/)

CarrassaLChilÃ RLupiMRicciFCelenzaCMazzolettiMBrogginiMDamiaG Combined inhibition of Chk1 and Wee1: In vitro synergistic effect translates to tumor growth inhibition in vivo Cell Cycle 2012 11 2507 17 10.4161/cc.20899
